It introduces the supervision mechanism of import and export of special products in our country and the United States in detail and compares them under the background of the rapid development of the biopharmaceutical industry, the increasing import and export volume of special products and the complex situation of the global new crown pneumonia epidemic. It analyzes the legislative loopholes, information islands, regulatory blind spots, regulatory gaps and detection difficulties in the supervision of special products in China. According to the above facts, we propose to establish a whole-chain management model for high-risk special products in China. On the premise of ensuring the safety supervision of high-risk special products, we suggest exploring and promoting the establishment of laws to adapt the biosafety situation nowadays and the supervision needs of special products. In addition to this, we also recommend to cooperate with multiple departments to optimize and improve the supervision mechanism for special products after entry. With above measures we can effectively solve the difficulties of entry inspection of special products and supervision blind spots, improve the level of customs clearance facilitation, make the supervision of entry high-risk special products more complete and efficient. It can support the biopharmaceutical industry to become bigger and stronger by these scientific means.